THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING
Dr. Clifford J. Rosen says he wants to avoid a repeat of the crisis triggered by reports of heart risks with the drug Avandia.
Dr. Clifford J. Rosen says he wants to avoid a repeat of the crisis triggered by reports of heart risks with the drug Avandia. (Jay Mallin/Bloomberg News) Jay Mallin/Bloomberg News

Burden of proof

Pointing to risks linked to FDA-approved drugs, a researcher argues that the agency should require more testing, a route some say could keep life-saving medication off the market for years

By Diedtra Henderson
Globe Staff / September 10, 2007

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size – +

A prominent New England researcher has rekindled a debate about the standards the Food and Drug Administration uses to speed approval of life-saving drugs, arguing that federal officials should insist on more rigorous proof that the drugs save lives and improve patients' health. (Full article: 1117 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $4.95 1 article
  • $9.95 4 articles
  • $25.95 Monthly